Epitope spreading is not required for relapses in experimental autoimmune encephalomyelitis

被引:23
作者
Jones, RE
Bourdette, D
Moes, N
Vandenbark, A
Zamora, A
Offner, H
机构
[1] Vet Adm Med Ctr, Res Serv, Portland, OR 97201 USA
[2] Oregon Canc Inst, Portland, OR 97239 USA
[3] Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97239 USA
关键词
D O I
10.4049/jimmunol.170.4.1690
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The sequential emergence of specific T lymphocyte-mediated immune reactivity directed against multiple distinct myelin epitopes (epitope spreading) has been associated with clinical relapses in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Based on this association, an appealing and plausible model for immune-mediated progression of the advancing clinical course in MS and EAE has been proposed in which epitope spreading is the cause of clinical relapses in T cell-mediated CNS inflammatory diseases. However, the observed association between epitope spreading and disease progression is not universal, and absolute requirements for epitope spreading in progressive EAE have not been tested in the absence of multiple T cell specificities, because most prior studies have been conducted in immunocompetent mouse strains that possessed broad TCR repertoires. Consequently, the precise nature of a causal relationship between epitope spreading and disease progression remains uncertain. To determine whether relapsing or progressive EAE can occur in the absence of epitope spreading, we evaluated the course of disease in mice which possessed only a single myelin-specific TCR. These mice (transgenic/SCID +/+) exhibited a progressive and sometimes remitting/relapsing disease course in the absence of immune reactivity to multiple, spreading myelin epitopes. The results provide direct experimental evidence relevant to discussions on the mechanisms of disease progression in MS and EAE. The Journal of Immunology, 2003.
引用
收藏
页码:1690 / 1698
页数:9
相关论文
共 35 条
[1]  
BHARDWAJ V, 1994, J IMMUNOL, V152, P3711
[2]   A SEVERE COMBINED IMMUNODEFICIENCY MUTATION IN THE MOUSE [J].
BOSMA, GC ;
CUSTER, RP ;
BOSMA, MJ .
NATURE, 1983, 301 (5900) :527-530
[3]   THE SCID MOUSE MUTANT - DEFINITION, CHARACTERIZATION, AND POTENTIAL USES [J].
BOSMA, MJ ;
CARROLL, AM .
ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 :323-350
[4]   On the accuracy and reliability of predictions by perceptual control theory: Five years later [J].
Bourbon, WT .
PSYCHOLOGICAL RECORD, 1996, 46 (01) :39-47
[5]   Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice [J].
Chen, YH ;
Hancock, WW ;
Marks, R ;
Gonnella, P ;
Weiner, HL .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 82 (02) :149-159
[6]   DEVELOPMENT OF REACTIVITY TO NEW MYELIN ANTIGENS DURING CHRONIC RELAPSING AUTOIMMUNE DEMYELINATION [J].
CROSS, AH ;
TUOHY, VK ;
RAINE, CS .
CELLULAR IMMUNOLOGY, 1993, 146 (02) :261-269
[7]  
Goverman J, 1996, LAB ANIM SCI, V46, P482
[8]   Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein [J].
Goverman, J .
IMMUNOLOGICAL REVIEWS, 1999, 169 :147-159
[9]   TRANSGENIC MICE THAT EXPRESS A MYELIN BASIC PROTEIN-SPECIFIC T-CELL RECEPTOR DEVELOP SPONTANEOUS AUTOIMMUNITY [J].
GOVERMAN, J ;
WOODS, A ;
LARSON, L ;
WEINER, LP ;
HOOD, L ;
ZALLER, DM .
CELL, 1993, 72 (04) :551-560
[10]  
Grogan JL, 1999, J IMMUNOL, V163, P3764